We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?
Read MoreHide Full Article
Key Takeaways
AbbVie's Q1 focus is immunology as Skyrizi and Rinvoq offset declining Humira sales post exclusivity loss.
ABBV expects Skyrizi and Rinvoq sales of $4.43B and $2.07B, driven by IBD growth and label expansions.
ABBV faces rising competition from J&J's Tremfya and Lilly's Omvoh in the immunology market.
AbbVie (ABBV - Free Report) is set to report first-quarter 2026 results on April 29, with investor focus likely to remain on its immunology segment. Following the loss of exclusivity (LoE) for its flagship drug, Humira, the company has been leaning heavily on Skyrizi and Rinvoq to drive growth.
AbbVie successfully launched Skyrizi and Rinvoq across Humira's major indications, and a distinct new indication, atopic dermatitis. Both drugs have delivered strong performance across approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes ulcerative colitis (UC) and Crohn’s disease (CD).
Continued momentum from these therapies, supported by market share gains and recent label expansions — including Skyrizi in UC and Rinvoq in giant cell arteritis (GCA) — is expected to drive immunology sales in the quarter. The Zacks Consensus Estimate for Skyrizi and Rinvoq sales is pegged at $4.43 billion and $2.07 billion, respectively, for the to-be-reported quarter, representing growth from the year-ago period.
Meanwhile, Humira sales are expected to decline significantly, with the Zacks Consensus Estimate pegged at $723 million for the quarter.
Beyond immunology, AbbVie has been expanding its presence in other therapeutic areas, notably neuroscience and oncology. Growth in its neuroscience franchise has been supported by the increasing uptake of its oral migraine therapies, Ubrelvy and Qulipta. In oncology, the company has successfully broadened its portfolio beyond hematologic cancers into solid tumors, led by newer assets such as Elahere and Emrelis.
ABBV’s Competition in the Immunology Space
The immunology market is highly competitive. A key player in this field is Johnson & Johnson (JNJ - Free Report) , which already markets two blockbuster drugs — Stelara and Tremfya. These medications are approved across multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity last year, J&J has shifted its focus to Tremfya. It recently secured approval for a new immunology drug, Icotyde, for the treatment of moderate-to-severe plaque psoriasis. While still in the early stages of launch, the drug could pose a competitive threat to Skyrizi.
Another pharma giant expanding its presence in immunology is Eli Lilly (LLY - Free Report) , following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked LLY’s first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its immunology portfolio. The Eli Lilly drug received FDA approval for the CD indication last year.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 13.92 times forward earnings, lower than its industry’s average of 17.27.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2026 has declined from $14.54 to $14.53, while those for 2027 have fallen from $16.23 to $16.14 over the past 30 days.
View the Zacks #1 Rank List
Image: Shutterstock
How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?
Key Takeaways
AbbVie (ABBV - Free Report) is set to report first-quarter 2026 results on April 29, with investor focus likely to remain on its immunology segment. Following the loss of exclusivity (LoE) for its flagship drug, Humira, the company has been leaning heavily on Skyrizi and Rinvoq to drive growth.
AbbVie successfully launched Skyrizi and Rinvoq across Humira's major indications, and a distinct new indication, atopic dermatitis. Both drugs have delivered strong performance across approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes ulcerative colitis (UC) and Crohn’s disease (CD).
Continued momentum from these therapies, supported by market share gains and recent label expansions — including Skyrizi in UC and Rinvoq in giant cell arteritis (GCA) — is expected to drive immunology sales in the quarter. The Zacks Consensus Estimate for Skyrizi and Rinvoq sales is pegged at $4.43 billion and $2.07 billion, respectively, for the to-be-reported quarter, representing growth from the year-ago period.
Meanwhile, Humira sales are expected to decline significantly, with the Zacks Consensus Estimate pegged at $723 million for the quarter.
Beyond immunology, AbbVie has been expanding its presence in other therapeutic areas, notably neuroscience and oncology. Growth in its neuroscience franchise has been supported by the increasing uptake of its oral migraine therapies, Ubrelvy and Qulipta. In oncology, the company has successfully broadened its portfolio beyond hematologic cancers into solid tumors, led by newer assets such as Elahere and Emrelis.
ABBV’s Competition in the Immunology Space
The immunology market is highly competitive. A key player in this field is Johnson & Johnson (JNJ - Free Report) , which already markets two blockbuster drugs — Stelara and Tremfya. These medications are approved across multiple immunology indications, including UC and CD. Since Stelara lost U.S. patent exclusivity last year, J&J has shifted its focus to Tremfya. It recently secured approval for a new immunology drug, Icotyde, for the treatment of moderate-to-severe plaque psoriasis. While still in the early stages of launch, the drug could pose a competitive threat to Skyrizi.
Another pharma giant expanding its presence in immunology is Eli Lilly (LLY - Free Report) , following the FDA approval of Omvoh for the UC indication in late 2023. Omvoh marked LLY’s first immunology drug approved for a type of IBD in the United States, playing a key role in expanding its immunology portfolio. The Eli Lilly drug received FDA approval for the CD indication last year.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have underperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a discount to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 13.92 times forward earnings, lower than its industry’s average of 17.27.
Image Source: Zacks Investment Research
The bottom-line estimate per share for 2026 has declined from $14.54 to $14.53, while those for 2027 have fallen from $16.23 to $16.14 over the past 30 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.